Rchr
J-GLOBAL ID:200901038641458479
Update date: Jul. 01, 2024
Miki Tsuneharu
ミキ ツネハル | Miki Tsuneharu
Research field (1):
Urology
Research keywords (4):
泌尿器科学
, 泌尿器科腫瘍学
, Urology
, Urologic oncology
Research theme for competitive and other funds (6):
前立腺肥大症の遺伝子多型の解析
精巣腫瘍の分化誘導療法
泌尿器癌の臨床的研究
study of genetic polymorphism in benign prostotic hyperplasia
Differentiation therapy for testicular cancer
Clinical study of urological Cancer
Show all
MISC (37):
Prostate-specitic trauscription facfor hpse in translated only in normal prostate epithelial cells. Cancer Res. 2000. 60. 1348-1352
Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladdercauce cells by autologeus non-activated peripheral blood lynphicytes and fumor intiltvatiug lymplocytes. Jownal of Orology. 1999. 162. 2170-2175
JD Wang, N Nonomura, S Takahara, BS Li, H Azuma, N Ichimaru, Y Kokado, K Matsumiya, T Miki, S Suzuki, et al. Lymphotactin: a key regulator of lymphocyte trafficking during acute graft rejection. IMMUNOLOGY. 1998. 95. 1. 56-61
T Miki, N Nonomura, M Nozawa, Y Harada, K Nishimura, Y Kojima, S Takahara, A Okuyama. Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line. JOURNAL OF UROLOGY. 1998. 160. 1. 210-213
Y Yasunaga, M Shin, T Miki, A Okuyama, K Aozasa. Prognostic factors of renal cell carcinoma: A multivariate analysis. JOURNAL OF SURGICAL ONCOLOGY. 1998. 68. 1. 11-18
more...
Books (2):
転移巣の病理組織像-組織学的効果判定
文光堂 1992
his topathological study of metastatic testicular cancer.
1992
Education (2):
- 1975 Osaka University Faculty of Medicine
- 1975 Osaka University Faculty of Medicine
Professional career (1):
Doctor of Medicine
Committee career (4):
日本がん検診・診断学会 評議員
日本性機能学会 理事
日本癌治療学会 評議員
日本泌尿器科学会 評議員
Association Membership(s) (8):
米国臨床癌学会(ASCO)
, 日本がん検診・診断学会
, 日本EE学会
, American Urological Association アメリカ泌尿器科学会
, 日本性機能学会
, 日本癌治療学会
, 日本癌学会
, 日本泌尿器科学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM